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Abstract
Purpose: The aim of this work is to identify new ligands targeting the platelet-derived growth
factor receptor beta (PDGFRβ).
Procedures: Biopanning was carried out with a 12-amino-acid phage display library against the
recombinant extracellular domain of PDGFRβ. The identified peptide PDGFR-P1 was
chemically synthesized and labeled with 125I or 131I. In vitro studies were performed on the
PDGFRβ-expressing cell lines BxPC3 and MCF7 and on PDGFRβ-transfected HEK cells in
comparison to negative control wtHEK293 and CaIX-transfected HEK cells. Biodistribution
experiments were performed in Balb/c nude mice, carrying subcutaneously BxPC3 tumors.
Results: In vitro studies demonstrated a higher binding to BxPC3, MCF7, and PDGFRβ-tr-HEK
cells in comparison to negative control cell lines. Binding was inhibited up to 90% by the
unlabeled PDGFR-P1 peptide. Organ distribution studies revealed a higher accumulation in
BxPC3 tumors than in most organs.
Conclusions: PDGFR-P1 is a promising candidate for targeting human PDGFRβ.
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Introduction
The platelet-derived growth factor receptor β (PDGFRβ)is a transmembrane glycoprotein that belongs to the
receptor tyrosine kinase family [1]. Activation through the
PDGF ligand leads to receptor dimerization, allowing the
phosphorylation of regulatory tyrosine residues. Phosphory-
lated receptor tyrosine residues bind SH2 domain-containing
proteins and initiate cytoplasmic signal transduction path-
ways that inﬂuence cell migration, proliferation, and
differentiation [2, 3].
PDGFRβ is found to be upregulated in various solid
tumors. The receptor is implicated in tumor growth mainly
through angiogenesis activation. The role of PDGF-B/
PDGFRβ signaling pathway in angiogenesis has been
extensively investigated in knockout animal models [4].
Such studies revealed that PDGFRβ expressing pericytes are
recruited by PDGF-B-producing endothelial cells to angio-
genic vessels, leading to stimulation of vascular smooth
muscle cells and therefore vessel maturation [5]. In addition,
signaling of PDGFRβ has a key role in the regulation of
tumor interstitial ﬂuid pressure [6]. Preclinical data have
revealed that targeting PDGFRβ results in a decrease of the
interstitial ﬂuid pressure, allowing a better transcapillary
molecular transport [7]. This effect has been the basis for the
initiation of clinical investigations of therapeutic approaches
combining chemotherapy drugs with PDGFR inhibitors [8].
The PDGF/PDGFR pathway has also a pivotal role in
radiation treatment outcome and toxicity. It has been shown
that PDGFR inhibitors enhance the antiangiogenic effects of
irradiation [9, 10]. Furthermore, PDGF signaling is involved
in the pathogenesis of radiation-induced pulmonary ﬁbro-
sis, with studies showing that treatment with receptorCorrespondence to: Vasileios Askoxylakis; e-mail: v.askoxylakis@dkfz.de
tyrosine kinase inhibitors could attenuate the development
of therapy-related lung ﬁbrosis [11]. Additionally, clinical
investigations revealed that PDGFRβ is not only strongly
expressed in different tumor types but that the protein
expression is important for disease prognosis [12]. A
recent analysis has demonstrated signiﬁcant associations
between the PDGFRβ status in prostate carcinomas with
histopathological tumor characteristics, such as Gleason
score and tumor stage and clinical characteristics, including
survival [13].
The role of PDGFRβ in various pathophysiological
mechanisms, including both tumor development and treat-
ment outcome, makes the receptor an attractive structure for
molecular targeting and imaging approaches. Ligands with
receptor speciﬁcity might be used for visualization of
angiogenesis, but also for imaging and prediction of
treatment response. Within the past years, a number of
PDGFRβ inhibitors targeting the kinase activity have been
developed and tested both in preclinical and clinical studies,
showing promising antitumor activity [14, 15]. However,
most of those inhibitors are not speciﬁc for PDGFRβ, but
also show activity to other kinases such as PDGFRα, BCR-
ABL, c-kit, or VEGF receptor.
Antibodies represent ligands with high target speciﬁcity.
Monoclonal antibodies (mAbs) or single chain variable
antibody fragments (scFv) targeting PDGFRβ have been
generated and investigated, demonstrating high target afﬁn-
ity and speciﬁcity [16, 17]. However, antibodies are known
to possess pharmacokinetic properties that might be disad-
vantageous for targeting or imaging applications. Due to
their high molecular weight, antibodies show a slow
extravasation from the blood supply and a limited, inho-
mogenous tumor penetration [18]. Furthermore, despite the
development of chimeric or humanized antibodies, the in vivo
use of antibodies is often limited by their immunogenic
potential [19]. As tools for imaging antibodies show
unfavorable characteristics, they are slowly cleared from
the blood, resulting in high background activity for extended
time periods and reduced imaging contrast due to low
signal-to-noise ratios [20].
Peptides are an attractive alternative to antibodies because
of their advantageous pharmacokinetic properties for tumor
targeting and imaging such as homogenous tumor penetration,
reduced immunogenic potential, and rapid blood clearance,
whereas they are easier and less expensive to generate [21].
Identiﬁcation of peptides with speciﬁc targeting characteristics
that could be used for both therapeutic and diagnostic
approaches is subject of intensive investigation in ligand-
related cancer research.
The aim of the present study is to identify peptides with
afﬁnity and speciﬁcity for the extracellular domain of the
human platelet-derived growth factor receptor β. Selection
panning was performed independently on immobilized target
protein and protein in suspension using the phage display
technology. The identiﬁed peptide ligand for both indepen-
dent biopanning processes was chemically synthesized,
radiolabeled, and characterized in vitro for afﬁnity and
speciﬁcity. In vivo organ distribution studies were
performed in mice bearing PDGFRβ overexpressing
tumors, and the peptide stability in human serum was
investigated.
Results
Selection of Peptides Binding the Extracellular
Domain of PDGFRβ
To identify human PDGFRβ speciﬁc binding peptides,
phage display was applied on immobilized recombinant
extracellular domain of PDGFRβ and on biotinylated target
in suspension. Extracellular domains of EGFR and FGFR
were used as negative control targets. After four selection
rounds, the same sequence was identiﬁed in both panning
strategies. In particular, 40% of the clones isolated on
immobilized protein and 80% of the clones isolated on
biotinylated target in suspension displayed the peptide
sequence: IPLPPPSRPFFK (Fig. 1).
Binding Experiments on Immobilized Protein
The identiﬁed peptide including a C-terminal tyrosine
residue for radiolabeling (PDGFR-P10IPLPPPSRPFFKY-
NH2) was chemically synthesized, labeled with
125I and
investigated on immobilized extracellular domains of
PDGFRβ, EGFR and FGFR. Binding of the radioligand
was about 18% on the extracellular domain of PDGFRβ.
Experiments on the negative control targets (EGFR and
FGFR) revealed only binding at the background level
(pG0.05) (Fig. 2).
In Vitro Binding Experiments on PDGFRβ-
Transfected Cells
In vitro binding of 125I-labeled PDGFR-P1 was investigated
on transfected HEK293 cells stably expressing PDGFRβ
(PDGFR-tr-HEK). Wild-type HEK cells (HEK293wt) and
human carbonic anhydrase IX (CaIX) transfected cells
(CaIX-tr-HEK) were used as negative control targets.
Kinetic studies revealed a signiﬁcantly increased binding of
PDGFR-P1 on PDGFR-tr-HEK cells compared to the
negative controls (Fig. 3a, b) (pG0.05). Peptide binding
correlated with the expression of PDGFRβ in the three cell
lines as evaluated by Western blot analysis (Fig. 3c) and
real-time PCR (Fig. 3d).
In Vitro Binding, Kinetic and Competition
Experiments on BxPC3 and MCF7 Cells
In vitro binding of 125I-labeled PDGFR-P1 was investigated
on the human pancreatic carcinoma cell line BxPC3 and the
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human breast cancer cell line MCF7. After cell blocking
with milk powder, cells were incubated with the radioligand
in serum-free medium to avoid peptide degradation. In vitro
kinetic experiments demonstrated an increase of radioligand
binding with time. In particular, a maximal binding capacity
of 9.5% and 5.2% applied dose per 106 cells was measured
for BxPC3 and MCF7 cells, respectively, which remained
stable for the investigated period of 6 h (Fig. 4a). Peptide
binding correlated with the expression of PDGFRβ in
BxPC3 and MCF7 cells as evaluated by Western blot
analysis (Fig. 4a). Co-incubation of 125I-labeled PDGFR-
P1 on BxPC3 cells with the unlabeled peptide at various
concentrations resulted in a concentration-dependent inhibi-
tion of radioligand binding, which reached a level of 90% at
a competitor concentration of 10−4 M (pG0.01). The IC50
value was calculated to be 1.4 μM (Fig. 4b). Competition
experiments were performed using random peptides as
negative control competitors, demonstrating that radioligand
binding could be strongly inhibited by unlabeled PDGFR-P1
but not by the other competitors, such as CaIX-P1 and DUP-
1-9 (Fig. 4c).
Internalization Experiments
In vitro internalization was investigated in BxPC3 cells.
After 60-min incubation with 125I-labeled PDGFR-P1, the
internalized radioactivity was measured to be 26% of the
total bound activity. Co-incubation with the unlabeled
peptide led to a signiﬁcant reduction of both total and
internalized radioactivity (pG0.05). Incubation at 4°C
resulted in a 65% reduction of the total bound activity and
a reduction of about 85% of the internalized activity. The
measured internalized activity was 1.15% applied dose per
106 cells at 37°C and 0.18% at 4°C (Fig. 4d).
Stability in Human Serum
Stability experiments revealed a rapid peptide degradation
through serum proteases. The serum half-life of 125I-labeled
PDGFR-P1 was 4 min. Degradation product analysis
revealed a cleavage of the C-terminal tyrosine over time
(Fig. 5).
Organ Distribution Studies
Biodistribution experiments of 131I-labeled PDGFR-P1 were
performed in mice, carrying subcutaneously transplanted
BxPC3 tumors. The organ distribution revealed a tumor
accumulation of 3.2% ID/g tissue after 15-min circulation.
Fig. 1. Schematic representation of the panning strategies applied on the extracellular domain of PDGFRβ. After four selection
rounds using different negative control targets (EGFR and FGFR), the dodecapeptide IPLPPPSRPFFK was identified by both
strategies.
Fig. 2. Binding of 125I-labeled PDGFR-P1 on the recombinant
extracellular domain of PDGFRβ, EGFR and FGFR. Mean
values and standard deviation.
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Tumor binding was higher compared to most healthy tissues
(Fig. 6). The values in blood and kidney were higher (5.4%
and 10.6% ID/g, respectively). To reduce blood background
in both tumor and healthy tissues, biodistribution experi-
ments were followed by perfusion with 0.9% NaCl. The
perfusion experiments revealed a reduction in most healthy
tissues, such as heart, lung, spleen, liver, kidney, and muscle
but not in the tumor. This resulted in an increase of the
tumor-to-organ ratios (Table 1), which was found to be
highly signiﬁcant for heart, lung, liver, kidney, and muscle
(pG0.01). In particular, the tumor-to-liver ratio was 0.906
before perfusion and 2.003 after perfusion (pG0.05). The
tumor-to-intestinum ratio showed no signiﬁcant increase
after animal perfusion.
Discussion
The platelet-derived growth factor receptor beta is a
transmembrane glycoprotein belonging to the tyrosine
kinase family. Protein stimulation by PDGF-B induces the
recruitment of pericytes and their integration in the vascular
wall, promoting angiogenesis [22]. PDGFRβ is expressed in
various solid tumors and is involved in important biological
processes, such as cell proliferation and regulation of the
tumor interstitial pressure [23].
The fact that PDGFRβ is expressed in malignant tumors
and that it is a transmembrane molecule and therefore easily
accessible makes the protein an attractive target for the
development of molecular targeting strategies for diagnosis
and therapy. In regard to molecular imaging, non-invasive
PDGFRβ visualization in solid tumors is important since it
could optimize treatment monitoring, allowing a detailed
evaluation of tumor response to therapeutic modalities.
A promising screening technology for identiﬁcation of
speciﬁc binding ligands is the phage display technology.
Recently, afﬁbody molecules, consisting of 58-amino-acid
three helical polypeptides with afﬁnity for PDGFRβ, were
isolated using phage display selection [24]. The identiﬁed
binders were highly speciﬁc, revealing reactivity only for
human and murine PDGFRβ and demonstrating a potential
for protein targeting.
However, although afﬁbody molecules are very attractive
alternatives to mAbs, there is still a need for development of
even smaller peptides for use in targeted approaches. Oligo-
peptides are characterized by advantageous characteristics
attributed to their small size, such as rapid blood clearance
and increased tumor penetration. Therefore, the aim of the
present study was to identify small peptide ligands with
speciﬁcity and afﬁnity for PDGFRβ. To isolate ligands with
high target speciﬁcity, two different phage display strategies
were performed independently from each other.Within the ﬁrst
Fig. 3. In vitro kinetics of 125I-labeled PDGFR-P1 in recombinant HEK293 cells stably overexpressing PDGFRβ (PDGFR-tr-HEK) in
comparison to wild-type HEK293 cells (a) and negative control HEK cells transfected with human carbonic anhydrase IX (CaIX-tr-
HEK) (b). Mean values and standard deviation. Expression of PDGFRβ in PDGFR-tr-HEK, HEK293wt, and CaIX-tr-HEK cells as
investigated by Western blot (c) and real-time PCR analysis (d).
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strategy, panning was carried out on the immobilized extracel-
lular domain of PDGFRβ, whereas the extracellular domain of
EGFR was used as negative control target. Within the second
strategy, panning was performed on the extracellular domain of
PDGFRβ in suspension and a different negative control target
(FGFR) was used. After several selection rounds, the same
dodecapeptide (IPLPPPSRPFFK) was identiﬁed for both
strategies, indicating a high PDGFRβ afﬁnity.
Speciﬁc ligand binding on PDGFRβ was demonstrated in
binding experiments using the radiolabeled, chemically
synthesized PDGFR-P1 peptide. In particular, experiments
on immobilized proteins showed a signiﬁcantly increased
binding on the extracellular domain of PDGFRβ compared
to the extracellular domains of the negative control targets
EGFR and FGFR. Furthermore, a signiﬁcantly increased
ligand binding was demonstrated on transfected HEK293
cells, stably overexpressing PDGFRβ, compared to both
wild-type HEK293 but also to negative control HEK293
cells transfected with human carbonic anhydrase IX.
Binding on transfected and wild-type cells was found to
correlate with the expression of PDGFRβ as investigated
both with real-time PCR and Western blot analysis, which
further strengthens the hypothesis of speciﬁc target binding.
To determine the properties of PDGFR-P1 on tumor cells,
the peptide binding was evaluated on human pancreatic
cancer BxPC3 and human breast cancer MCF7 cells. BxPC3
cells were chosen because this cell line is well established
and known to overexpress PDGFRβ [25]. The results of our
studies on BxPC3 and MCF7 cells were in concert with the
previous results and supported the hypothesis of speciﬁc
target binding. Kinetic analysis on both cell lines revealed an
increased binding on the strong PDGFRβ expressing BxPC3
cells and a correlation to the protein expression as
investigated by Western blot analysis. Competition experi-
ments on BxPC3 cells using the unlabeled peptide at various
concentrations revealed a concentration dependent inhibition
of radioligand binding. Furthermore, radioligand binding
could be inhibited by the unlabeled PDGFR-P1 peptide, but
not by other, randomly chosen, phage display peptides, such
as CaIX-P1 [26] or DUP-1–9 [27].
Although the in vitro results indicate a PDGFRβ
speciﬁcity, organ distribution analysis is necessary prior to
the use of a ligand for in vivo applications. In this respect, a
higher accumulation in the tumor, compared to the healthy
tissues and blood, is a prerequisite. Our in vivo biodistribu-
tion studies showed a higher accumulation in the tumor than
Fig. 4. In vitro characterization of 125I-labeled PDGFR-P1. aIn vitro kinetics on human pancreatic cancer BxPC3 and human
breast cancer MCF7 cells. Peptide binding correlated with the target expression as characterized by Western blot analysis. b
Displacement of bound 125I-labeled PDGFR-P1 by unlabeled PDGFR-P1 at various concentrations on BxPC3 cells. c Specific
binding of 125I-labeled PDGFR-P1 on BxPC3 cells. Non-specific binding was determined in the presence of 10−5 M unlabeled
PDGFR-P1. The peptides CaIX-P1 and DUP-1–9 were randomly used as negative control competitors at the same
concentration. d Binding and internalization of 125I-labeled PDGFR-P1 in BxPC3 cells. Cells were incubated with the
radioligand for 60 min at 37°C or at 4°C. The unlabeled peptide was used as competitor at a concentration of 10−5 M. Mean
values and standard deviation (n03).
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in most healthy tissues. In addition, perfusion experiments
resulted in a signiﬁcant accumulation decrease in most
healthy tissues but not in the tumor, leading to a signiﬁcant
increase of the tumor-to-organ ratios. The intestinal accu-
mulation did not decrease after animal perfusion, which
might be explained by the expression of PDGF receptors in
intestinal myoﬁbroblasts [28]. The fact that the radioactivity
level in the tumor remained constant after perfusion,
whereas it strongly decreased mainly in highly perfused
organs, such as heart, lung, and liver is evidence for a
speciﬁc tumor binding, but only an unspeciﬁc accumulation
in healthy organs as a result of a high blood pool
contribution. The high blood background represents a major
drawback in the use of the ligand for imaging purposes since
it results in enhanced background noise. A possible
explanation for the high blood levels is an interaction of
the ligand with serum proteins, such as albumin. A further
explanation is the peptide’s serum instability. Metabolic
studies revealed a rapid peptide degradation by serum
proteases, resulting in circulation of radiolabeled fragments.
Therefore, a major issue of further investigation is the
metabolic stabilization of PDGFR-P1. A systematic ap-
proach to achieve this goal includes the identiﬁcation of the
degradation site in the peptide sequence and the application
of targeted modiﬁcations that cannot be recognized by serum
proteases, such as exchange of amino acids by unnatural
amino acids (D- or N-methylated amino acids) [29], peptide
acetylation or pegylation [30, 31], or grafting of the binding
Fig. 5. Serum stability analysis of 125I-labeled PDGFR-P1. HPLC analysis of aliquots collected at time points from 0 to 20 h.
Fig. 6. Organ distribution of 131I-labeled PDGFR-P1 in Balb/c nu/nu mice carrying BxPC3 tumors. Black columns—activity
concentration (% ID/g) in tumor and control organs after 15-min circulation. Gray columns—radioactivity concentration (% ID/g)
in tumor and control organs after perfusion of the animals (n03 animals per experiment).
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motif into a stable scaffold structure [32]. In addition, the
IC50 value of 1.4 μM shows that an afﬁnity improvement is
needed. In this direction, peptide dimerization or multi-
merization can be applied. Peptide homodimers or homo-
multimers are usually characterized by improved target
afﬁnity compared to their monomers, mainly due to
optimized cooperative receptor–ligand interactions as a
result of increased ligand concentration [33]. Considering
the dimeric nature of PDGFRβ, dimerization might also
enhance the afﬁnity of PDGFR-P1, a hypothesis that needs
to be further investigated.
In conclusion, the results of our studies indicate that
PDGFR-P1 might be a promising candidate for the devel-
opment of novel peptide-based ligands, targeting the
platelet-derived growth factor receptor beta. Such ligands
could be used for visualization of PDGFRβ expression in
tumors and their vasculature, as well as for monitoring
treatment response. However, prior to the use of the peptide
for imaging or targeting applications, it is of highest priority
to improve its metabolic stability and promote the develop-




All cell lines were cultivated at 37°C in a 5% CO2 incubator. The
human pancreatic carcinoma cell line BxPC3, the recombinant cell
lines PDGFRβ-tr-HEK and CaIX-tr-HEK, and wild-type HEK293
cells (HEK293wt) were cultivated in RPMI medium, supplemented
with 10% FCS (Invitrogen). The human breast cancer cell line
MCF7 was cultured in DMEM with Glutamax, containing 10%
FCS (Invitrogen).
Recombinant Isolation of the Extracellular
Domain of Human PDGFRβ
The extracellular domain of PDGFRβ was recombinantly synthe-
sized using the Flp-In system (Invitrogen Life Technologies) as
described [26]. PCR ampliﬁcation of the sequence encoding for the
target was performed using a pCMV-SPORT6 vector including the
PDGFRβ gene (ImaGenes, Germany). The primers for PCR
ampliﬁcation were forward: 5′-AAC TTA AGC TTG GGG CCG
CCA CCA TGC GGC TTC CGG GTG CGA-3′ and reverse: 5′-
GGC TCC GGA TCC ATG TCC CTG CCC TCG ATC TTA AAG
GGC AAG GAG TGT GG-3′. After PCR ampliﬁcation, the
sequence was inserted into the HindIII and BspEI sites of a
pSEC-EGP-2-Fcγ vector (Afﬁmed, Heidelberg, Germany). The
fragment PDGFRβ-Fc was cut by HindIII and XhoI, inserted into a
pcDNAEpcam vector (Afﬁmed), and transfected with the Flp
recombinase expression vector pOG44 into the Flp-InTM-293
human embryonic kidney host cell line. After selection for
hygromycin resistance, cells excreting the fusion protein were
seeded in CELLine AD 1000 ﬂasks (Integra) and 5 L of culture
medium were collected. Protein puriﬁcation was carried out using a
HiTrapTM MabSelect SuReTM column, and Western blot analysis as
well as ELISA was applied for qualitative control (data not shown).
Establishment of a Cell Line Permanently
Expressing PDGFRβ
PCR ampliﬁcation of the coding sequence of PDGFRβ was carried
out. The primers used were forward: 5′-GAT GAT ATC ATG CGG
CTT CCG GGT GCG A-3′ and reverse: 5′-ATC GAT ATC CTA
CAG GAA GCT ATC CTC TGC-3′. The ampliﬁed sequence was
digested with EcoRV and inserted into the SmaI site of pSKE-
F1αIIIVSIREShyg vector (own lab construct). The construct was
then cut by SalI blunt and NsiI. After insertion into the XhoI blunt
and NsiI sites of M48EF1αDmdNkIVSIREShyg vector (own lab
construct), stable transfection of HEK293 cells was performed,
using the LipofectAMINE PLUS Reagent package (Invitrogen Life
Science), according to the manufacturer’s protocol. RNA was
isolated using the TRIzol method (TRIzol Reagent, Invitrogen) and
mRNA expression of PDGFRβ was assessed by real-time PCR as
described below. Protein expression from selected clones was
veriﬁed by Western blot analysis as described below.
Selection of Peptides Binding PDGFRβ
Peptide selection was performed using a commercial 12-amino-acid
peptide library (Ph.D.12; New England Biolabs). The recombinant
extracellular domain of PDGFRβ was used as target, either
immobilized in 96-well plates or biotinylated in suspension.
Immobilized recombinant extracellular domain of the epidermal
growth factor receptor (EGFR) and biotinylated extracellular
domain of the ﬁbroblast growth factor receptor (FGFR) were used
for negative selection, respectively.
Panning on Immobilized Target
Each selection round was conducted as previously described [26]:
1011 plaque-forming units were added on immobilized negative
target (EGFR) in 96-well plates. After incubation for 1 h at room
temperature, medium containing unbound phages was transferred
on the immobilized positive target (PDGFRβ) and further incubated
for 1 h at room temperature. Thereafter, medium was removed, the
positive target was washed 10 times with 100 μl TBST and the
bound phages were eluted through incubation with 10 μl 0.2 M
glycine/HCl buffer pH 2.2, containing 1 mg/ml BSA. The eluent
Table 1. Tumor-to-organ ratios calculated from the organ distribution of
131I-labeled PDGFR-P1 in Balb/c nu/nu mice carrying BxPC3 tumors before
and after organ perfusion (n03 animals per experiment)









218 V. Askoxylakis et al.: Peptide-Based Targeting of the Platelet-Derived Growth Factor Receptor Beta
was neutralized with 15 μl Tris/HCl buffer pH 9.1, and centrifuged
for 5 min at 1,000 rpm. Ten microliter supernatant aliquots were
used for phage titration on IPTG/X-Gal (Fermentas) lysogeny broth
agar plates.
Panning with Biotinylated Target in Suspension
Both positive (PDGFRβ) and negative (FGFR) target were
biotinylated as follows: 20 μl of 10 mM EZ-LinkSulfo-NHS-LC-
Biotin (Pierce, Rockford, IL, USA) was added to 1 ml target in
PBS pH 7.4 and mixed well. The biotinylation was accomplished
when the mixture stood at 4°C for about 2 h. The free biotin reagent
was removed by dialysis in PBS pH 7.4 at 4°C. Each selection
round was conducted as follows: 1011 plaque-forming units were
added in 500 μl PBST supplemented with 0.1% BSA pH 7.0. After
30-min incubation, 50 μl Dynabeads® M-280 Streptavidin (Invi-
trogen) was added together with 100 μl biotinylated negative target
FGFR 100 nM and 100 μl non-biotinylated FGFR 1,000 nM. After
1-h incubation at room temperature, the unbound phages were
separated with a Dynal magnet and incubated with 100 μl
biotinylated PDGFRβ for 1 h at room temperature. Fifty microliters
of Dynabeads® M-280 Streptavidin was added and after further 15-
min incubation the PDGFRβ-bound phages were separated with a
Dynal magnet. The beads were washed with 1,000 μl PBST/0.1%
BSA pH 7.0 and the bound phages were eluted with 1000 μl 0.2 M
glycine/HCl buffer pH 2.2. The magnetic beads were separated
with the Dynal magnet and neutralization was performed with 15 μl
Tris/HCl buffer pH 9.1. Supernatant was collected and 10 μl was
used for phage titration on IPTG/X-Gal (Fermentas) lysogeny broth
agar plates.
Phage Ampliﬁcation and Sequencing
Bound phages were ampliﬁed in 20 ml of ER2537 bacteria
according to the manufacturer’s protocol. After four selection
rounds, single-stranded phage DNA was isolated from picked
clones using a QIAprep Spin M13 Kit (Qiagen). The sequence of
the displayed peptide was identiﬁed through DNA sequencing and
analysis using the HUSAR map (HUSAR Biocomputing Service at
the German Cancer Research Center), as previously described [26].
Peptides
The peptide PDGFR-P1 (IPLPPPSRPFFKY-NH2) was synthesized
on an ABI433A peptide synthesis reactor (Applied Biosystems)
using Fmoc coupling protocols. Peptide puriﬁcation was performed
by high performance liquid chromatography (HPLC) on a Chro-
molith Semi Prep Column RPe18, 10×100 mm (Merck), with a
linear gradient of water and acetonitrile containing 0.1% triﬂuoro-
acetic acid. After lyophilization of the product, mass analysis was
performed on a matrix-assisted laser desorption ionization time-of-
ﬂight mass spectrometer (MALDI-3; Kratos instruments). The
chloramine-T method was used for peptide labeling with 125I or 131I
[34]. HPLC puriﬁcation of the iodinated product was carried out on a
Chromolith Performance RP-18e 100×4.6 mm column (Merck). The
speciﬁc activities for the 125I- and the 131I-labeled peptides were about
50 GBq/μmol.
Binding Experiments on Immobilized Protein
Binding of 125I-labeled PDGFR-P1 was investigated on immobilized
extracellular domain of human PDGFRβ, EGFR, and FGFR. The
target proteins were incubated at a concentration of 25 nM in 96-well
MaxisorpTM plates (Nunc GmbH & Co. KG, Germany) for 24 h and
the plates were washed thrice with 100 μl PBS pH 7.4. 125I-labeled
PDGFR-P1 was incubated with the target in 100 μl PBS pH 7.4 for
60 min. The unbound activity was removed by washing with 300 μl
ice-cold PBS pH 7.4. Bound radioligand was determined through
degradation with 100 μl NaOH 0.3 M and radioactivity measurement.
Radioligand binding was calculated as percentage applied dose.
In Vitro Binding Experiments
Three hundred thousand BxPC3, MCF7, PDGFRβ-tr-HEK, CaIX-
tr-HEK, or HEK293wt cells were cultivated in six-well plates at
37°C for 24 h. Cells were blocked with RPMI 1640 containing 1%
milk powder and the medium was replaced with 1 ml fresh medium
(without FCS) containing 0.5–1.5×106 cpm 125I-labeled peptide.
After incubation at 37°C for various time periods (10 min to 6 h),
the medium was removed and the cells were washed with PBS.
Subsequently, cell lysis was performed with 0.5 ml NaOH 0.3 M
and the bound radioactivity was measured with a γ-counter and
calculated as percentage applied dose per 106 cells. Speciﬁc
binding was determined through co-incubation of the radioligand
with the unlabeled PDGFR-P1 peptide at various concentrations
(10−4 to 10−10 M). A dodecapeptide identiﬁed with phage display
by panning against the extracellular domain of human carbonic
anhydrase IX (CaIX-P1) [26] as well as a derivative of a
dodecapeptide identiﬁed with phage display on prostate carcinoma
cells (DUP-1–9) [27] were used as negative control competitors.
Internalization Studies
Subconﬂuent cell cultures of BxPC3 cells were incubated with 125I-
labeled PDGFR-P1 for 60 min at 37°C and 4°C. After cell washing
with PBS, incubation was performed with 1 ml glycine–HCl
50 mmol/l in PBS (pH 2.8) for 10 min at room temperature in order
to remove the membrane bound activity. Internalized activity was
determined through subsequent cell lysis with 0.5 ml NaOH 0.3 M
and measurement with a γ-counter as previously described.
Stability Studies
The stability of PDGFR-P1 was investigated in human serum. 125I-
labeled peptide was incubated at 37°C in human serum. At time
points varying from 5 min to 20 h, aliquots were taken, mixed with
equal volume acetonitrile, to precipitate serum proteins and
centrifuged for 5 min at 13,000 rpm. Serum degradation products
were determined by HPLC analysis of the supernatant.
In Vivo Experiments
Organ distribution studies were carried out in 9-week-old female
Balb/c nu/nu mice (Charles River WIGA), carrying subcutaneously
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transplanted human pancreatic cancer BxPC3 tumors. Tumor
implantation was performed through injection of a cell suspension
(4×106 cells in OPTI-MEM) (Gibco, Invitrogen Life Technologies)
into the mouse trunk. After the tumors were grown to a size of
approximately 1.0 cm3, 1 MBq of 131I-labeled PDGFR-P1 was
injected into the tail vein, and at 15 min p.i. the animals were
euthanized. Tumor, blood, and healthy tissues were removed,
weighed, and measured with a γ-counter (LB 951G; Berthold
Technologies). Organ uptake calculation was performed as per-
centage injected dose per gram tissue (% ID/g). To avoid bias due
to blood background radioactivity, uptake in blood-free organs was
determined with perfusion experiments [35]. Within these experi-
ments, blood was removed through a catheter in the ascending aorta
of the anesthesized animal and perfusion with approximately 25 ml
0.9% NaCl was performed via a cut in the animal liver. After
perfusion, samples of tumor and organs were removed and
measured as described. All animal experiments were carried out
in conformity with the German and European laws for animal
protection.
Real-Time Quantitative PCR
Total cellular RNA was isolated from conﬂuent PDGFRβ-tr-HEK,
CaIX-tr-HEK, and HEK293wt cells using the Trizol method (TRIzol
Reagent, Invitrogen) and a standard phenol–chloroform RNA extrac-
tion protocol. Five hundred nanograms of RNA was transcribed into
DNA using M-MLV reverse transcriptase, 50 pmol random hexamer,
and 100 pmol of oligo(dT) primers (Promega, Madison, WI, USA).
Relative mRNA transcript levels for PDGFRβ were quantiﬁed
applying the TaqMan methodology on a StepOnePlusTM Real-Time
PCR System (Applied Biosystems). Normalization was performed
using GAPDH as housekeeping gene. All primers were obtained from
Applied Biosystems (Foster City, CA, USA).
Western Blot Analysis
BxPC3, MCF7, HEK293wt, PDGFRβ-tr-HEK, and CaIX-tr-HEK
cells were grown to 80% conﬂuency. After cell washing with PBS
and lysis with 1 ml cell lysis buffer (1 M Tris, 5 M NaCl, 1 mM
EDTA, 1 mM EGTA, pH 8.01), centrifugation at 13,000 rpm was
performed for 10 min at 4°C. The supernatant was collected for
Western blot analysis as described [9]. In particular, protein transfer
from a polyacrylamide gel to a nitrocellulose membrane was
performed using a Mini Trans-Blotter (100 V for 90 min).
Subsequently, the membranes were blocked with 5% non-fat milk
powder in TBST buffer for 1 h at room temperature and incubation
with a mouse IgG1 monoclonal anti-human PDGFRβ antibody
(R&D Systems) was carried out overnight at 4°C. The nitrocellu-
lose membrane was washed with TBST and incubated with a
horseradish peroxidase conjugated antibody in blocking buffer at
room temperature for 60 min. Antibody binding was determined
using a chemiluminescence detection system with exposures
recorded on hyperﬁlms for 10 s to 3 min.
Statistics
Data were analyzed employing the paired two-tailed Student t test
and signiﬁcance was assumed at p G0.05.
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